varespladib methyl
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Introduction: Cardiovascular disease is the most common cause of morbidity and mortality worldwide. Inflammation is responsible…
Certain members of the phospholipase A(2) superfamily of enzymes have established causal involvement in atherosclerosis, thus at…
BackgroundThe action of secretory phospholipase A2 (sPLA2) on lipoproteins may render them more susceptible to oxidation, thereby…
AIMS
To investigate the effects of secretory phospholipase A2 (sPLA(2)) inhibition on plasma lipoproteins. Secretory…
PurposeSecretory phospholipase A2 group IIA (sPLA2−IIA) concentration and activity are associated with increased risk of…
Secretory phospholipase A(2) (sPLA(2)) represents a family of isoenzymes that participate in lipoprotein and inflammatory…
Importance of the field: The high risk of recurrent cardiovascular events amongst patients with cardiovascular disease receiving…
Purpose of review Selective inhibitors of secretory phospholipase A2 and lipoprotein-associated phospholipase A2 are potential…
Varespladib methyl is an oral secretory phospholipase A2 inhibitor that is being developed by Anthera Pharmaceuticals Inc for the…